Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Venetoclax-based therapy as a bridge to allogeneic hematopoietic cell transplantation in children with relapsed/refractory AML

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Fig. 1: Key transplant outcomes.

Data availability

For data sharing, contact the corresponding authors at pthomas@wustl.edu or swati.naik@stjude.org.

References

  1. Karol SE, Alexander TB, Budhraja A, Pounds SB, Canavera K, Wang L, et al. Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study. Lancet Oncol. 2020;21:551–60.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  2. DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7–17.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  3. Kharfan-Dabaja MA, Kumar A, Ayala E, Aljurf M, Nishihori T, Marsh R, et al. Standardizing definitions of hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on Behalf of the American Society for Transplantation and Cellular Therapy. Transpl Cell Ther. 2021;27:642–9.

    Article  CAS  Google Scholar 

  4. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295–304.

    Article  PubMed  CAS  Google Scholar 

  5. DiNardo CD, Rausch CR, Benton C, Kadia T, Jain N, Pemmaraju N, et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018;93:401–7.

    Article  PubMed  CAS  Google Scholar 

  6. Wei AH, Strickland SA, Hou JZ, Fiedler W, Lin TL, Walter RB, et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study. J Clin Oncol. 2019;37:1277–84.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. Naik S, Talleur AC, Li Y, Madden RM, Mamcarz E, Qudeimat A, et al. CD45RA-depleted haploidentical transplantation combined with NK cell addback results in promising long-term outcomes in pediatric patients with high-risk hematologic malignancies. Blood. 2021;138(Suppl 1):172.

    Article  Google Scholar 

  8. Gabriel SS, Bon N, Chen J, Wekerle T, Bushell A, Fehr T, et al. Distinctive expression of Bcl-2 factors in regulatory T cells determines a pharmacological target to induce immunological tolerance. Front Immunol. 2016;7:73.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Strobl J, Pandey RV, Krausgruber T, Kleissl L, Reininger B, Herac M, et al. Anti-apoptotic molecule BCL2 is a therapeutic target in steroid-refractory graft-versus-host disease. J Invest Dermatol. 2020;140:2188–98.

    Article  PubMed  CAS  Google Scholar 

  10. Davis JE, Du K, Ludford-Menting MJ, Prabahran A, Wong E, Huntington ND, et al. Venetoclax or ruxolitinib in pre-transplant conditioning lowers the engraftment barrier by different mechanisms in allogeneic stem cell transplant recipients. Front Immunol. 2021;12:749094.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Contributions

TP and SN conceived and designed the retrospective study. Patient enrollment and management: SEK, JER, RE, RM, EM, EO, AQ, A Sharma, A Srinivasan, A Suliman, ACT, MPV, and BMT. Analysis and interpretation of data: TP, SN, YL, and EA. Writing of the manuscript: TP, SN, BMT, and SG. Review/revision of the manuscript: all authors.

Corresponding authors

Correspondence to Thomas Pfeiffer or Swati Naik.

Ethics declarations

Competing interests

SG and MPV are a co-inventors on patent applications in the fields of cell or gene therapy for cancer. SG is a consultant of TESSA Therapeutics, a member of the Data and Safety Monitoring Board (DSMB) of Immatics, and has received honoraria from Tidal, Catamaran Bio, Sanofi, and Novartis within the last 2 years. Author A Sharma has received consultant fees from Spotlight Therapeutics, Medexus Inc. and Vertex Pharmaceuticals, has received research finding from CRISPR Therapeutics and honoraria from Vindico Medical Education. All other authors have no conflict of interest to disclose.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Pfeiffer, T., Li, Y., Ashcraft, E. et al. Venetoclax-based therapy as a bridge to allogeneic hematopoietic cell transplantation in children with relapsed/refractory AML. Bone Marrow Transplant (2022). https://doi.org/10.1038/s41409-022-01877-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1038/s41409-022-01877-2

Search

Quick links